| Patient | Friedrich Nietzsche |
|---|---|
| Date of birth | 1989-10-15 |
| Identifiers | MRN HR-NI019-SYN; SSN (made up) 000-19-5523 |
| Document date | 2026-09-15 |
| Author | Konrad Ellison-Mbatha, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review of migraine prevention after the withdrawal. [S]
Mr. Nietzsche returns eight weeks after starting galcanezumab and five weeks after the last butalbital tablet. His diary shows 7 headache days in the past four weeks, 4 with migraine features, and no attack lasting more than a day. He used acute medicine on 5 days: sumatriptan on 3, with relief within two hours in 2, and naproxen on 2. He has taken no combination tablets. The injections cause only brief redness, and his constipation is unchanged. The floaters in his right eye have nearly gone, with no new flashes. He sleeps about six hours after five CBT-I sessions. His mood is good. His HIV, hepatitis C and hepatitis B tests from the preventive visit were negative, and he was told by phone. He is writing for several hours on most days and walking as before. [S]
| Element | Detail |
|---|---|
| Headache days | 7 in the past four weeks, 4 with migraine features (from about 20 and 12 before treatment) |
| Acute medicine | 5 days: sumatriptan on 3, naproxen on 2 |
| Disability | MIDAS 31 (grade IV), from 74; HIT-6 58, from 68 |
| Mood | PHQ-9 4; GAD-7 3 |
| Sleep | About six hours |
| Screening results | HIV, hepatitis C and hepatitis B negative |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | Floaters nearly gone; no flashes, shadow or distortion on the Amsler grid |
| Gastrointestinal | Negative | No nausea between attacks; constipation unchanged |
| Neurological | Positive | Seven headache days in four weeks; no new features |
| Psychiatric | Negative | Mood good; PHQ-9 4 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad) | One or two tablets as needed, about 16 days a month, up to four a day | Oral route | 2025-11-03 to 2026-07-21 | stopped | S |
| Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter) | Two tablets as needed, about 4 days a month | Oral route | 2025-11-03 to 2026-07-21 | stopped | S |
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stop | Scheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra doses | Oral route | 2026-07-21 to 2026-08-10 | completed | S |
| Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week | One tablet at attack onset, may repeat once after 12 hours; no more than two days a week | Oral route | 2026-07-21 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week | One tablet with the acute medicine when nausea is present, no more than once a day | Oral route | 2026-07-21 | active | S |
| Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention | Loading dose of 240 mg (two injections) on the first day, then 120 mg every four weeks | Subcutaneous route | 2026-07-21 | active | S |
| Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month | One tablet at attack onset, may repeat once after 2 hours; up to 200 mg a day, no more than eight days a month | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-15 | Body height | 174 | cm | S |
| 2026-09-15 | Body weight | 67 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 62 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-15 | Because of your headaches on how many days in the last 3 months did you miss work or school [PhenX] | 6 | d | S | ||
| 2026-09-15 | Because of your headaches on how many days in the last 3 months was your productivity at work or school reduced by half or more [PhenX] | 10 | d | S | ||
| 2026-09-15 | Because of your headaches on how many days in the last 3 months did you not do household work [PhenX] | 3 | d | S | ||
| 2026-09-15 | Because of your headaches on how many days in the last 3 months was your productivity in house-hold work reduced by half or more [PhenX] | 5 | d | S | ||
| 2026-09-15 | Because of your headaches on how many days in the last 3 months did you miss family, social, or leisure activities [PhenX] | 7 | d | S | ||
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-09-15 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S |
Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 112/72, pulse 62 |
| Eyes | Repeat dilated examination of the right eye: the vitreous detachment is complete, with no retinal break or detachment; macula unchanged |
| Neurological | Normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultation | resolved | confirmed | R51.9 | S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache. |
| Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differently | active | confirmed | G43.709 | S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis. |
| Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawal | resolved | confirmed | G44.40 | S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines. |
| High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination booked | active | confirmed | H52.13 | S — Synthetic modern coding of his documented severe myopia. |
| Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eye | active | confirmed | H44.2E1 | S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes. |
| Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intake | active | confirmed | G47.00 | S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep. |
| Acute posterior vitreous detachment of the right eye, with flashes and a floater, without a retinal break, detachment or vitreous hemorrhage on dilated examination, in an eye with pathologic myopia | resolved | confirmed | H43.811 | S — Synthetic acute eye problem in a highly myopic eye; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache days, migraine days, attack features, triggers | Every visit | Completed today | 7 headache days and 4 migraine days in four weeks |
| Medication safety | Acute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15) | Every visit | Completed today | Acute medicine on 5 days: sumatriptan on 3, naproxen on 2; no combination tablets |
| Medication safety | Galcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivity | Before starting and at each injection visit | Completed today | Brief redness only; constipation unchanged; blood pressure 112/72; third dose given today |
| Examination | Preventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month) | At three months on treatment | Due | Early response at eight weeks (migraine days 12 to 4); formal judgment at the three-month review |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after two to three months of treatment | Completed today | MIDAS items 6, 10, 3, 5 and 7 days, total 31 (grade IV), from 74; the recall includes the weeks before treatment; HIT-6 58, from 68 |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harm | At baseline and at two to three months; questions at every visit | Completed today | PHQ-9 4, item 9 scored 0; GAD-7 3 |
| Examination | Dilated re-examination after an acute posterior vitreous detachment | Within six weeks of the detachment, sooner with new symptoms | Completed today | Six weeks after the detachment: complete, with no retinal break or detachment |
| Examination | Comprehensive eye examination: refraction, pupils, pressure, dilated fundus examination, macular OCT | At diagnosis, then yearly for pathologic myopia, and urgently for new flashes, floaters or a shadow | Up to date | Comprehensive examination eight weeks ago; next in one year |
| Self-management | Sleep: hours, sleep diary, insomnia severity; no sedative sleeping tablets | Every visit | Completed today | About six hours after five CBT-I sessions; no sleeping tablets |
| Self-management | Reading, writing and walking plan | Every visit | Completed today | Writing several hours a day with breaks; daily walks continue |
Goal progress:
Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation (2018); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Three-month review in four weeks, before he leaves for the winter, with the fourth injection and a plan for care by the sea. Second hepatitis B vaccine dose in two weeks. [S]